Cargando…

Therapeutic potential of Fingolimod in triple negative breast cancer preclinical models

Surgery followed by a chemotherapy agent is the first-line treatment for breast cancer patients. Nevertheless, new targets are required for women with triple-negative breast cancer (TNBC) in order to improve the treatment of this aggressive cancer subtype. Multiple pro-inflammatory molecules includi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rupp, Tristan, Pelouin, Océane, Genest, Laurie, Legrand, Christophe, Froget, Guillaume, Castagné, Vincent
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2020
Materias:	Original article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7649527/ https://www.ncbi.nlm.nih.gov/pubmed/33157518 http://dx.doi.org/10.1016/j.tranon.2020.100926

Ejemplares similares

Evaluation of Temozolomide and Fingolimod Treatments in Glioblastoma Preclinical Models
por: Davy, Mélodie, et al.
Publicado: (2023)

Therapeutic Potential of Fingolimod and Dimethyl Fumarate in Non-Small Cell Lung Cancer Preclinical Models
por: Rupp, Tristan, et al.
Publicado: (2022)

Anti-CTLA-4 and anti-PD-1 immunotherapies repress tumor progression in preclinical breast and colon model with independent regulatory T cells response
por: Rupp, Tristan, et al.
Publicado: (2022)

A Face-To-Face Comparison of Tumor Chicken Chorioallantoic Membrane (TCAM) In Ovo with Murine Models for Early Evaluation of Cancer Therapy and Early Drug Toxicity
por: Rupp, Tristan, et al.
Publicado: (2022)

Triple Negative Breast Cancer Preclinical Therapeutic Management by a Cationic Ruthenium-Based Nucleolipid Nanosystem
por: Ferraro, Maria Grazia, et al.
Publicado: (2023)

Tumor Metabolism Is Affected by Obesity in Preclinical Models of Triple-Negative Breast Cancer
por: Yelek, Caner, et al.
Publicado: (2022)

Preclinical Evaluation of Fingolimod in Rodent Models of Stroke With Age or Atherosclerosis as Comorbidities
por: Diaz Diaz, Andrea C., et al.
Publicado: (2022)

Pathogenesis and Potential Therapeutic Targets for Triple-Negative Breast Cancer
por: Li, Chia-Jung, et al.
Publicado: (2021)

On the Therapeutic Potential of ERK4 in Triple-Negative Breast Cancer
por: Boudghene-Stambouli, Fadia, et al.
Publicado: (2022)

Ferroptosis and triple-negative breast cancer: Potential therapeutic targets
por: Xu, Na, et al.
Publicado: (2022)

Molecular Pharmacology and Novel Potential Therapeutic Applications of Fingolimod
por: Pournajaf, Safura, et al.
Publicado: (2022)

Activity of Indatuximab Ravtansine against Triple-Negative Breast Cancer in Preclinical Tumor Models
por: Schönfeld, Kurt, et al.
Publicado: (2018)

MYC as a therapeutic target for the treatment of triple-negative breast cancer: preclinical investigations with the novel MYC inhibitor, MYCi975
por: Tang, Minhong, et al.
Publicado: (2022)

The Potential Role of Nanotechnology in Therapeutic Approaches for Triple Negative Breast Cancer
por: Johnson, Rebecca, et al.
Publicado: (2013)

Therapeutic potential of ERK5 targeting in triple negative breast cancer
por: Ortiz-Ruiz, María Jesús, et al.
Publicado: (2014)

Proteins Found in the Triple-Negative Breast Cancer Secretome and Their Therapeutic Potential
por: McHenry, Peter R., et al.
Publicado: (2023)

Therapeutic Potential of Tumor Metabolic Reprogramming in Triple-Negative Breast Cancer
por: Munkácsy, Gyöngyi, et al.
Publicado: (2023)

Triple-Negative Breast Cancer: Adjuvant Therapeutic Options
por: Gucalp, Ayca, et al.
Publicado: (2011)

Therapeutic landscape in mutational triple negative breast cancer
por: Shi, Yaqin, et al.
Publicado: (2018)

Targeted Therapeutic Strategies for Triple-Negative Breast Cancer
por: Li, Ying, et al.
Publicado: (2021)

Characterization of triple‐negative breast cancer preclinical models provides functional evidence of metastatic progression
por: Arroyo‐Crespo, Juan J., et al.
Publicado: (2019)

Triple-Negative Breast Cancer: A Review of Conventional and Advanced Therapeutic Strategies
por: Medina, Mauricio A., et al.
Publicado: (2020)

Identification of three subtypes of triple-negative breast cancer with potential therapeutic implications
por: Jézéquel, Pascal, et al.
Publicado: (2019)

Evaluating the therapeutic potential of ADAR1 inhibition for triple-negative breast cancer
por: Kung, Che-Pei, et al.
Publicado: (2020)

Therapeutic Strategies for Metastatic Triple-Negative Breast Cancers: From Negative to Positive
por: Nandini, Dey, et al.
Publicado: (2021)

Novel therapeutic strategies for patients with triple-negative breast cancer
por: Zhang, Jun-Fei, et al.
Publicado: (2016)

CAPER as a therapeutic target for triple negative breast cancer
por: Campbell, Mallory C., et al.
Publicado: (2018)

Novel therapeutic strategies in the treatment of triple-negative breast cancer
por: Oualla, Karima, et al.
Publicado: (2017)

Emerging Therapeutic Drugs in Metastatic Triple-Negative Breast Cancer
por: Cipriano, Élia, et al.
Publicado: (2021)

Molecular Targets and Promising Therapeutics of Triple-Negative Breast Cancer
por: Ryu, Won-Ji, et al.
Publicado: (2021)

Recent advances in therapeutic strategies for triple-negative breast cancer
por: Li, Yun, et al.
Publicado: (2022)

CXCR2 Levels Correlate with Immune Infiltration and a Better Prognosis of Triple-Negative Breast Cancers
por: Boissière-Michot, Florence, et al.
Publicado: (2021)

Therapeutic impact of Nintedanib with paclitaxel and/or a PD-L1 antibody in preclinical models of orthotopic primary or metastatic triple negative breast cancer
por: Reguera-Nuñez, Elaine, et al.
Publicado: (2019)

Determination of Seminal Concentration of Fingolimod and Fingolimod‐Phosphate in Multiple Sclerosis Patients Receiving Chronic Treatment With Fingolimod
por: David, Olivier J., et al.
Publicado: (2017)

Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer
por: Arango, Natalia Paez, et al.
Publicado: (2017)

Identification of nuclear export inhibitor-based combination therapies in preclinical models of triple-negative breast cancer
por: Rashid, Narmeen S., et al.
Publicado: (2021)

Is immune checkpoint modulation a potential therapeutic option in triple negative breast cancer?
por: Klinke, David J
Publicado: (2014)

Potential therapeutic targets of triple-negative breast cancer based on its intrinsic subtype
por: Shao, Fangyuan, et al.
Publicado: (2017)

PKD1 is a potential biomarker and therapeutic target in triple-negative breast cancer
por: Spasojevic, Caroline, et al.
Publicado: (2018)

Therapeutic Potential of Chemically Modified miR-489 in Triple-Negative Breast Cancers
por: Soung, Young Hwa, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_e2t47asto3ge0vagnhger2gmul